TriangleNCT03591510 · CITED IN SOURCE DOCUMENTS
A Global Study of Midostaurin in Combination With Chemotherapy to Evaluate Safety, Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Patients With FLT3 Mutated AML
An NCI or FDA source cites this study. A citation does not establish that it applies to an individual diagnosis.
- Phase
- PHASE2
- Status at capture
- ACTIVE NOT RECRUITING
- Registry last update
- 2026-07-09
This study will evaluate the safety, efficacy and pharmacokinetics of midostaurin in combination with standard chemotherapy in pediatrics patients with newly diagnosed FLT3-mutated Acute Myeloid Leukemia. The study has two parts: Part 1 to define the Recommended Phase 2 Dose, and Part 2 to evaluate safety and tolerability and efficacy of midostaurin. Both parts will consist of 2 induction blocks, 3 consolidation blocks, 12 cycles of post-consolidation consisting of continuous therapy with midostaurin, and a follow-up phase.
Open the original ClinicalTrials.gov record → · Download preserved record
What did the study report?
Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.
No posted result sections were captured. Registered plans do not establish that a treatment works.
Who could take part
- eligibility Criteria
- Inclusion Criteria: * Documented Diagnosis of previously untreated de novo AML according to WHO 2016 criteria * Presence of a FLT3 mutation status as measured/confirmed by a designated lab with results available prior first dose of Midostaurin * Patients with Lansky or Karnofsky performance status equal or superior to 60 * Patient with the following laboratory value : AST and ALT ≤ 3times ULN * Serum Total bilirubin ≤ 1.5times ULN * Estimated creatinine clearance ≥30ml/min Exclusion Criteria: * Any concurrent malignancy, AML with Philadelphia Chromosome, AML-DS, JMML * Symptomatic leukemic CNS involvement * Isolated extramedullary leukemia, secondary AML and MDS * Acute Promyelocytic Leukemia with the PML RARA rearrangement * Patient who have received prior treatment with a FLT3 inhibitor. However, up to 1 week of FLT3 inhibitor (except midostaurin) exposure prior to study enrollment is permissible. Other protocol-defined inclusion/exclusion criteria may apply
- healthy Volunteers
- false
- maximum Age
- 17 Years
- minimum Age
- 3 Months
- sex
- ALL
- std Ages
- CHILD
Treatment arms and interventions
- arm Groups
- description
- In Part 1, midostaurin with standard induction (Block 1 induction according to local practice, Block 2 induction containing fludarabine, cytarabine, daunorubicin/idarubicin) and consolidation (Block 3: cytarabine + mitoxantrone, Block 4: cytarabine + etoposide, Block 5: cytarabine) followed by single agent midostaurin post-consolidation therapy. In Part 2, midostaurin with standard induction (Block 1 induction according to local practice, Block 2 induction containing cytarabine + mitoxantrone) and consolidation (Block 3: cytarabine + etoposide, Block 4: cytarabine + mitoxantrone, Block 5: cytarabine) followed by single agent midostaurin post-consolidation therapy.
- intervention Names
- Drug: Midostaurin
- Drug: Fludarabine
- Drug: Cytarabine
- Drug: Daunorubicin or idarubicin
- Drug: Mitoxantrone
- Drug: Etoposide
- label
- Chemotherapy followed by Midostaurin
- type
- EXPERIMENTAL
- interventions
- arm Group Labels
- Chemotherapy followed by Midostaurin
- description
- midostaurin 30mg/m2 bid
- name
- Midostaurin
- other Names
- PKC412
- type
- DRUG
- arm Group Labels
- Chemotherapy followed by Midostaurin
- description
- 30mg/m2/day on D1-D5 of Block 2 FLADx
- name
- Fludarabine
- other Names
- Part 1 Block 2 induction FLADx
- type
- DRUG
- arm Group Labels
- Chemotherapy followed by Midostaurin
- description
- Part 1: 2000mg/m2/day D1 to D5 of Block 2 FLADx 1000mg/m2 every 12 hours D1 to D3 Block 3 HAM 3000mg/m2 every 12 hours D1 to D3 Block 4 HA3E 3000mg/m2 every 12 hours D1 to D3 Block 5 HIDAC Part 2: 1000mg/m2 every 12 hours D1 to D3 Block 2 HAM 3000mg/m2 every 12 hours D1 to D3 Block 3 HA3E 1000mg/m2 every 12 hours D1 to D3 Block 4 HAM 3000mg/m2 every 12 hours D1 to D3 Block 5 HIDAC
- name
- Cytarabine
- other Names
- Part 1:
- Block 2 induction FLADx
- Block 3 consolidation HAM
- Block 4 consolidation HA3E
- Block 5 consolidation HIDAC
- Part 2:
- Block 2 induction HAM
- Block 3 consolidation HA3E
- Block 4 consolidation HAM
- type
- DRUG
- arm Group Labels
- Chemotherapy followed by Midostaurin
- description
- daunorubicin 60 mg/m2/day OR idarubicin 12mg/m2/day On D2, D4, D6 of Block 2 FLADx
- name
- Daunorubicin or idarubicin
- other Names
- Part 1 Block 2 induction FLADx
- type
- DRUG
- arm Group Labels
- Chemotherapy followed by Midostaurin
- description
- 10mg/m2/day D3 and D4
- name
- Mitoxantrone
- other Names
- Part 1:
- Block 3 consolidation HAM
- Part 2:
- Block 2 induction HAM
- Block 4 consolidation HAM
- type
- DRUG
- arm Group Labels
- Chemotherapy followed by Midostaurin
- description
- 100mg/m2/day D1 to D5
- name
- Etoposide
- other Names
- Part 1:
- Block 4 consolidation HA3E
- Part 2:
- Block 3 consolidation HA3E
- type
- DRUG
Study design
- allocation
- NA
- intervention Model
- SINGLE_GROUP
- masking Info
- masking
- NONE
- primary Purpose
- TREATMENT
Enrollment
- count
- 22
- type
- ACTUAL
Registered outcome plans (not posted results)
- primary Outcomes
- description
- Dose-limiting toxicity (DLT) is defined as any death due to toxicity related to study treatment (chemotherapy + midostaurin) and/or any CTCAE grade 4 non-hematological adverse event or abnormal laboratory value grade 4 related to study treatment unless the event improves sufficiently by day 42 and therefore does not further delay the next cycle of study treatment.
- measure
- Part 1 of the study: Occurence of dose limiting toxicities (DLT)
- time Frame
- From the start of midostaurin treatment in Block 1 to the end of Block 2, from Day 1 to Day 84
- description
- Safety profile includes type, frequency and severity of adverse events during the induction, consolidation and post consolidation phase. AEs are also collected during post treatment follow-up phase
- measure
- Part 2 of the study: To evaluate Safety of midostaurin (30mg/m2 bid or 1 mg/kg bid for participants <10 kg body weight) in sequential combination with chemotherapy followed by 12 cycles of midostaurin post-consolidation therapy.
- time Frame
- From the start of treatment up to 5 years follow-up of last patient
- description
- Number of dose interruptions/reductions and discontinuations due to study drug
- measure
- Part 2 of the study: To evaluate Tolerability of midostaurin (30mg/m2 bid or 1 mg/kg bid for participants <10 kg body weight) in sequential combination with chemotherapy followed by 12 cycles of midostaurin post-consolidation therapy.
- time Frame
- From the start of treatment up to 5 years follow-up of last patient
- secondary Outcomes
- description
- Percentage of participants with a response of CR, CRi or modified CRi at the end of Block 2
- measure
- Part 2 of the study: Percentage of participants with response (CR, CR/modified CRi and CR/CRi)
- time Frame
- From the start of treatment in Block 1 to the end of Block 2, from Day 1 up to Day 84
- description
- TTR is defined as the time between start of treatment to the date of first onset of response (CR, CRi or modified CRi). Response duration is defined as the time from CR, CRi or modified CRi to relapse or death due to any cause.
- measure
- Part 2 of the study: Time to response (TTR) and response duration
- time Frame
- From the start of treatment up to 5 years follow-up of last patient
- description
- EFS is defined as the time from Day 1 of chemotherapy until an EFS event is observed. An EFS event is defined as a failure to obtain CR/Modified CRi within induction, relapse after CR/modified CRi, or death due to any cause, whichever occurs first. EFS will be measured after all participants completed at least 18 months of follow-up.
- measure
- Part 2 of the study: Event Free Survival (EFS)
- time Frame
- From the start of treatment to time when all patients have completed at least 18 months of follow up (~ 48 months)
- description
- OS is defined as the time from Day 1 of chemotherapy to the date of death due to any cause.
- measure
- Part 2 of the study: Overall Survival (OS)
- time Frame
- At each visit, every 3 months after last follow-up visit and up to 5 years after last patient first treatment
- description
- DFS is defined as the time from CR/modified CRi in induction to relapse or death due to any cause
- measure
- Part 2 of the study: Disease free survival (DFS)
- time Frame
- From the start of treatment up to 5 years follow-up of last patient
- description
- Percentage of patient with MRD negative status by multiparameter flow cytometry
- measure
- Part 2 of the study: Percentage of participants with MRD negative status during each study phase
- time Frame
- MRD is evaluated at Day 14 after end of chemotherapy induction Block 1, at Day 21 of Blocks 2, 3, 4 and 5, and Cycle 7 during post-consolidation phase (each block could last up to 42 days)
- description
- Palatability is assessed through questionnaires- Palatability PRO and obsPRO
- measure
- Part 2 of the study: Palatability of oral solution of midostaurin
- time Frame
- Day 14 after end of chemotherapy induction Block 1, Day 21 of Blocks 2, 3, 4 and 5 (each block can last up to 42 days), post-consolidation Cycle 1, Cycle 3, Cycle 5, Cycle 7, Cycle 9, Cycle 11
- description
- Bone marrow and peripheral blood parameters and extramedullar involvement at the end of induction Block 1 and Block 2
- measure
- Part 2 of the study: Percentage of blasts in bone marrow and peripheral blood
- time Frame
- Parameters are assessed 14 days after end of chemotherapy induction Block 1 and Day 14 induction Block 2
- description
- Plasma concentration of midostaurin and its 2 metabolites
- measure
- Part 1 and Part 2 of the study: Plasma concentrations of midostaurin and its metabolites
- time Frame
- Days 1, 7 & 14 after end of local chemotherapy-induction in Block 1, Days 14 & 21 of Block 2, Day 21 of Blocks 3, 4 & 5 (each block can last up to 42 days), in-post consolidation Day 1 of Cycle (C)2, C3, C5, C7, C9 and C12 (each cycle = 28 days)
Full study description
- brief Summary
- This study will evaluate the safety, efficacy and pharmacokinetics of midostaurin in combination with standard chemotherapy in pediatrics patients with newly diagnosed FLT3-mutated Acute Myeloid Leukemia. The study has two parts: Part 1 to define the Recommended Phase 2 Dose, and Part 2 to evaluate safety and tolerability and efficacy of midostaurin. Both parts will consist of 2 induction blocks, 3 consolidation blocks, 12 cycles of post-consolidation consisting of continuous therapy with midostaurin, and a follow-up phase.
- detailed Description
- This trial is an open label, multi center single arm study to evaluate twice daily oral midostaurin with standard induction, consolidation chemotherapy with sequential midostaurin therapy for 5 treatment blocks (2 induction blocks, 3 consolidation blocks, followed by single agent midostaurin post consolidation therapy for 12 cycles). The total maximum planned duration on treatment is 17 cycles (5 blocks and 12 cycles). A block is defined as the time from start of study treatment to the time of hematopoietic recovery, at the latest at Day (D) 42, or determination of persistent disease, whichever occur first. In both Part 1 and Part 2, patients will receive the first course of induction chemotherapy according to local standard and duration is from 8 to 12 days. Upon FLT3 mutation confirmation, patients will receive midostaurin for 14 days. After determination of remission and hematopoietic recovery, patients will receive Block 2. In Part 1: * Block 2 FLADx treatment duration is D1 to D6, and midostaurin from D8 to D21. Patients who achieve documented CR (and hematopoietic recovery at the latest at D42 from the first day of Block 2) will receive Block 3. * Block 3 consolidation HAM treatment duration is D1 to D4, followed by midostaurin D8 to D21. Patients who achieve hematopoietic recovery at the latest at D42 from the first day of Block 3 will receive Block 4. Patients who relapse will discontinue further study treatment. * Block 4 HA3E treatment duration is D1 to D5 followed by midostaurin D8 to D21. Patients who achieve hematopoietic recovery at the latest at D42 from the first day of Block 4 will receive Block 5. * Block 5 HiDAC treatment duration is D1 to D3 followed by midostaurin D8 to D21. Patients who relapse will discontinue further study treatment. Patients in continuous remission with hematopoietic recovery will receive continuous post consolidation therapy of midostaurin, during 12 cycles (28 days per cycle). In Part 1 of the study, patients in cohorts of 3 will receive sequential midostaurin administered at 30mg/m2bid. If the 30mg/m2 bid is well tolerated as measured by the Dose Limited Toxicity (DLT) rate during Bock 1, additional patients in cohort of 3 will be treated with sequential midostaurin at 60mg/m2 bid. When the recommended phase 2 dose (RP2D) is confirmed, subsequent patients will be treated in Part 2 of the study at the RP2D. In Part 2: * Block 2 HAM treatment duration is D1 to D4 and midostaurin from D8 to D21. Patients who achieve documented CR (and hematopoietic recovery at the latest at D42 from the first day of Block 2) will receive Block 3. * Block 3 consolidation HA3E treatment duration is D1 to D5, followed by midostaurin D8 to D21. Patients who achieve hematopoietic recovery at the latest at D42 from the first day of Block 3 will receive Block 4. Patients who relapse will discontinue further study treatment. * Block 4 HAM treatment duration is D1 to D4 followed by midostaurin D8 to D21. Patients who achieve hematopoietic recovery at the latest at D42 from the first day of Block 4 will receive Block 5. * Block 5 HiDAC treatment duration is D1 to D3 followed by midostaurin D8 to D21. Patients who relapse will discontinue further study treatment. Patients in continuous remission with hematopoietic recovery will receive continuous post consolidation therapy of midostaurin, during 12 cycles (28 days per cycle). Patients who relapse will discontinue further study treatment.
Source references
Source notices and limitations
Discovery and provenance
- release id
- ctgov-registry-7ad944f6deaf1f5cd6122126
- edge id
- nct-edge-1d4efebbe7e177ebd93b
- requested nct id
- NCT03591510
- primary nct id
- NCT03591510
- source kind
- fda_spl_label
- source record id
- bc6574c1-6e9f-4aee-a755-517388595ef0
- source file sha256
- a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6
- payload sha256
- 833ce3224f61cfd5bd0f82970919dc292429ef11081520e3739496e757082bcf
- payload
- application numbers
- NDA207997
- clinical indication matching status
- not_inferred
- end exclusive
- true
- id
- nct-edge-1d4efebbe7e177ebd93b
- link basis
- explicit_NCT_identifier_in_acquired_source
- nct id
- NCT03591510
- occurrences
- context exact
- emia [NCT00866281] and a study in 4 patients aged 8 to 14 years who received midostaurin in combination with chemotherapy for newly diagnosed FLT3-mutated AML [NCT03591510]. Prolonged Grade 4 neutropenia and thrombocytopenia occurred in 2 of the 4 pediatric patients with AML who received midostaurin in combination with chemothera
- end
- 5321
- exact text
- NCT03591510
- start
- 5310
- offset unit
- unicode_code_points
- source file
- /tmp/cancer-full-research/indications/raw/labels-00600.json
- source file sha256
- a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6
- source json pointer
- /results/32/use_in_specific_populations/0
- source kind
- fda_spl_label
- source record id
- bc6574c1-6e9f-4aee-a755-517388595ef0
- source string basis
- parsed_JSON_string_unmodified
- source string sha256
- c529b0a33450424ec004df8250420b95cc0527247d875813fd4cab4822917f82
- spl effective time
- 20260608
- spl set id
- 11fa3fc9-6776-49a6-b1c1-653f627c3e58
- release id
- ctgov-registry-7ad944f6deaf1f5cd6122126
- edge id
- nct-edge-39d237883d7186677db4
- requested nct id
- NCT03591510
- primary nct id
- NCT03591510
- source kind
- fda_spl_label
- source record id
- bc6574c1-6e9f-4aee-a755-517388595ef0
- source file sha256
- a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6
- payload sha256
- 7a808e2dd7c827f1240a7c9f5630cbf32a8a98d0bfe4a1fee3851cbe5dd6caa5
- payload
- application numbers
- NDA207997
- clinical indication matching status
- not_inferred
- end exclusive
- true
- id
- nct-edge-39d237883d7186677db4
- link basis
- explicit_NCT_identifier_in_acquired_source
- nct id
- NCT03591510
- occurrences
- context exact
- emia [NCT00866281] and a study in 4 patients aged 8 to 14 years who received midostaurin in combination with chemotherapy for newly diagnosed FLT3-mutated AML [NCT03591510]. Prolonged Grade 4 neutropenia and thrombocytopenia occurred in 2 of the 4 pediatric patients with AML who received midostaurin in combination with chemothera
- end
- 541
- exact text
- NCT03591510
- start
- 530
- offset unit
- unicode_code_points
- source file
- /tmp/cancer-full-research/indications/raw/labels-00600.json
- source file sha256
- a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6
- source json pointer
- /results/32/pediatric_use/0
- source kind
- fda_spl_label
- source record id
- bc6574c1-6e9f-4aee-a755-517388595ef0
- source string basis
- parsed_JSON_string_unmodified
- source string sha256
- cb872639a3f179ec6b9860a082421eab5814b1133bb6ee0975f4ac6ffb7bb4d7
- spl effective time
- 20260608
- spl set id
- 11fa3fc9-6776-49a6-b1c1-653f627c3e58
- release id
- ctgov-registry-7ad944f6deaf1f5cd6122126
- edge id
- nct-edge-e97dd28bf0b63aafbd0a
- requested nct id
- NCT03591510
- primary nct id
- NCT03591510
- source kind
- nci_explicit_reference_or_link
- source record id
- Source null
- source file sha256
- 8e7cc2e32fc51992c491e61751eea5c12733e2487675051b006bf5d81066b2f7
- payload sha256
- 440c62aabbbd718e1b9fc9382a10c0a937af4ef8f6167ef76107a8e5bb96db9e
- payload
- clinical indication matching status
- not_inferred
- end exclusive
- true
- id
- nct-edge-e97dd28bf0b63aafbd0a
- link basis
- explicit_NCT_identifier_in_acquired_source
- nct id
- NCT03591510
- occurrences
- context exact
- _2010" tabindex="-1">A phase II trial is under way in Europe, beginning with the 30 mg/m<span class="sup">2</span> twice-daily dosing (<a href="/clinicaltrials/NCT03591510">NCT03591510</a>).</p> </section> <section id="_2169"> <h6 id="_2169_toc">Gilteritinib</h6> <p id="_2170" tabindex=
- end
- 477815
- exact text
- NCT03591510
- start
- 477804
- context exact
- ex="-1">A phase II trial is under way in Europe, beginning with the 30 mg/m<span class="sup">2</span> twice-daily dosing (<a href="/clinicaltrials/NCT03591510">NCT03591510</a>).</p> </section> <section id="_2169"> <h6 id="_2169_toc">Gilteritinib</h6> <p id="_2170" tabindex="-1">As in de
- end
- 477828
- exact text
- NCT03591510
- start
- 477817
- offset unit
- unicode_code_points
- source file
- /tmp/cancer-full-research/nci/raw/73204a34a100b0fa2e.html
- source file sha256
- 8e7cc2e32fc51992c491e61751eea5c12733e2487675051b006bf5d81066b2f7
- source json pointer
- Source null
- source kind
- nci_explicit_reference_or_link
- source record id
- Source null
- source retrieved at
- 2026-09-09T23:21:53.537755+00:00
- source string basis
- UTF-8_text_with_universal_newline_translation
- source string sha256
- 74fb97edc9145215f8b85c366e8cc116f08a5151772cf550992345b297a46bf0
- source title
- Childhood Acute Myeloid Leukemia Treatment (PDQ®)–Health Professional Version
- source update dates
- context
- Updated: April 15, 2025
- datetime
- 2025-04-15T12:00:00Z
- display
- April 15, 2025
Preserved source evidence · Not medical advice